affectsCellType
P94935
predicate
Indicates that one entity produces an effect or change on a specific type of cell.
Observed surface forms (5)
- actsOnCellType ×12
- targetCellType ×6
- cellTypeReprogrammed ×3
- effectOnBCells ×1
- effectOnCell ×1
Sample triples (34)
| Subject | Object |
|---|---|
| Dravet syndrome | GABAergic interneurons ⓘ |
| Krabbe disease | Schwann cells NERFINISHED ⓘ |
| Krabbe disease | oligodendrocytes ⓘ |
| LOXO-305 | B lymphocytes via predicate surface "actsOnCellType" ⓘ |
| Riabni | B lymphocytes ⓘ |
| TDP-43 proteinopathy | cortical neurons ⓘ |
| TDP-43 proteinopathy | hippocampal neurons ⓘ |
| TDP-43 proteinopathy | motor neurons ⓘ |
|
vascular endothelial growth factor A
surface form:
Vascular endothelial growth factor A
|
endothelial cell via predicate surface "actsOnCellType" ⓘ |
|
vascular endothelial growth factor A
surface form:
Vascular endothelial growth factor A
|
vascular smooth muscle cell (indirectly) via predicate surface "actsOnCellType" ⓘ |
| Yamanaka factors | convert differentiated cells to pluripotent state via predicate surface "effectOnCell" ⓘ |
| Yamanaka factors Oct3/4, Sox2, Klf4, and c-Myc | human fibroblasts via predicate surface "cellTypeReprogrammed" ⓘ |
| Yamanaka factors Oct3/4, Sox2, Klf4, and c-Myc | mouse fibroblasts via predicate surface "cellTypeReprogrammed" ⓘ |
| Yamanaka factors Oct3/4, Sox2, Klf4, and c-Myc | various somatic cell types via predicate surface "cellTypeReprogrammed" ⓘ |
| chronic lymphocytic leukemia | B lymphocyte NERFINISHED ⓘ |
| daratumumab | malignant plasma cell via predicate surface "targetCellType" ⓘ |
| daratumumab | normal plasma cell via predicate surface "targetCellType" ⓘ |
| fingolimod | B lymphocytes ⓘ |
| fingolimod | T lymphocytes NERFINISHED ⓘ |
| interleukin-4 | B cell via predicate surface "actsOnCellType" ⓘ |
| interleukin-4 | T helper cell via predicate surface "actsOnCellType" ⓘ |
| interleukin-4 | eosinophil via predicate surface "actsOnCellType" ⓘ |
| interleukin-4 | macrophage via predicate surface "actsOnCellType" ⓘ |
| interleukin-4 | mast cell via predicate surface "actsOnCellType" ⓘ |
| isatuximab | CD38-expressing hematologic tumor cells via predicate surface "actsOnCellType" ⓘ |
| isatuximab | malignant plasma cells via predicate surface "actsOnCellType" ⓘ |
|
mosunetuzumab (bispecific antibody component)
surface form:
mosunetuzumab
|
B lymphocytes via predicate surface "actsOnCellType" ⓘ |
|
mosunetuzumab (bispecific antibody component)
surface form:
mosunetuzumab
|
B-cell depletion via predicate surface "effectOnBCells" ⓘ |
|
mosunetuzumab (bispecific antibody component)
surface form:
mosunetuzumab
|
T lymphocytes via predicate surface "actsOnCellType" ⓘ |
| platelet-derived growth factor | fibroblasts via predicate surface "targetCellType" ⓘ |
| platelet-derived growth factor | glial cells via predicate surface "targetCellType" ⓘ |
| platelet-derived growth factor | mesenchymal cells via predicate surface "targetCellType" ⓘ |
| platelet-derived growth factor | smooth muscle cells via predicate surface "targetCellType" ⓘ |
| trapped neutrophil syndrome | neutrophil ⓘ |